Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and Response
- 16 December 1982
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 307 (25) , 1558-1560
- https://doi.org/10.1056/nejm198212163072505
Abstract
GENETIC polymorphism in the oxidative metabolism of debrisoquine1 is largely responsible for individual differences in its plasma concentration and antihypertensive effect.2 Poor hydroxylators have urinary debrisoquine:4-hydroxydebrisoquine ratios that are higher than 20, whereas extensive hydroxylators have ratios that are less than 12.5.3 , 4 The prevalence of the poor hydroxylator phenotype is about 9 per cent in the United Kingdom3 but it varies widely among ethnic groups, from 1 per cent in Arabs to 30 per cent in Hong Kong Chinese.5 The prevalence of this phenotype in the United States has not been reported, but among whites in Canada it appears to . . .Keywords
This publication has 18 references indexed in Scilit:
- Comparison of two long‐acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.British Journal of Clinical Pharmacology, 1982
- Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.British Journal of Clinical Pharmacology, 1982
- Genetic polymorphism of phenformin 4-hydroxylationClinical Pharmacology & Therapeutics, 1982
- The Upjohn Award Lecture 1981/La Conférence Upjohn 1981: The metabolism of xenobiotics in different populationsCanadian Journal of Physiology and Pharmacology, 1982
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Deficient metabolism of debrisoquine and sparteineClinical Pharmacology & Therapeutics, 1980
- Polymorphism of carbon oxidation of drugs and clinical implications.BMJ, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1977
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Why hypertensive patients vary in their response to oral debrisoquine.BMJ, 1977